These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 34396463)

  • 1. Rituximab for non-infectious Uveitis and Scleritis.
    Ng CC; Sy A; Cunningham ET
    J Ophthalmic Inflamm Infect; 2021 Aug; 11(1):23. PubMed ID: 34396463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab for treatment of non-infectious and non-malignant orbital inflammatory disease.
    Ng CC; Sy A; Cunningham ET
    J Ophthalmic Inflamm Infect; 2021 Aug; 11(1):24. PubMed ID: 34448063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab in the treatment of refractory scleritis in patients with granulomatosis with polyangiitis (Wegener's).
    Recillas-Gispert C; Serna-Ojeda JC; Flores-Suárez LF
    Graefes Arch Clin Exp Ophthalmol; 2015 Dec; 253(12):2279-84. PubMed ID: 26507398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclophosphamide or Rituximab Treatment of Scleritis and Uveitis for Patients with Granulomatosis with Polyangiitis.
    Ahmed A; Foster CS
    Ophthalmic Res; 2019; 61(1):44-50. PubMed ID: 29635229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab in the Treatment of Non-Infectious Uveitis: A Review.
    Cao H; Ma X
    J Inflamm Res; 2024; 17():6765-6780. PubMed ID: 39364118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological therapy in refractory cases of uveitis and scleritis: An analysis of 18 cases from a tertiary eye care center from South India.
    Sadhu S; Dutta Majumder P; Biswas J
    Indian J Ophthalmol; 2020 Sep; 68(9):1929-1933. PubMed ID: 32823417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab for noninfectious uveitis.
    Miserocchi E; Modorati G
    Dev Ophthalmol; 2012; 51():98-109. PubMed ID: 22517208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab Induction and Maintenance Treatment in Patients with Scleritis and Granulomatosis with Polyangiitis (Wegener's).
    You C; Ma L; Lasave AF; Foster CS
    Ocul Immunol Inflamm; 2018; 26(8):1166-1173. PubMed ID: 28628344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab).
    Heiligenhaus A; Miserocchi E; Heinz C; Gerloni V; Kotaniemi K
    Rheumatology (Oxford); 2011 Aug; 50(8):1390-4. PubMed ID: 21378109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subconjunctival Rituximab Administration for the Treatment of Scleritis.
    Vergouwen DPC; Ten Berge JC; Naus-Postema NC; Rothova A
    Ocul Immunol Inflamm; 2022 Aug; 30(6):1309-1311. PubMed ID: 35171758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of uveitis and scleritis patients in Malaysia.
    Seow ST; Tajunisah I; Lee FY; Lott PW; Reddy SC
    Int J Ophthalmol; 2024; 17(3):518-527. PubMed ID: 38721518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis.
    Sobrin L; Christen W; Foster CS
    Ophthalmology; 2008 Aug; 115(8):1416-21, 1421.e1. PubMed ID: 18221998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Necrotising Scleritis and Peripheral Ulcerative Keratitis Associated with Rheumatoid Arthritis Treated with Rituximab.
    Hardy S; Hashemi K; Catanese M; Candil M; Zufferey P; Gabison E; Guex-Crosier Y
    Klin Monbl Augenheilkd; 2017 Apr; 234(4):567-570. PubMed ID: 28147401
    [No Abstract]   [Full Text] [Related]  

  • 14. Rituximab therapy for refractory scleritis: results of a phase I/II dose-ranging, randomized, clinical trial.
    Suhler EB; Lim LL; Beardsley RM; Giles TR; Pasadhika S; Lee ST; de Saint Sardos A; Butler NJ; Smith JR; Rosenbaum JT
    Ophthalmology; 2014 Oct; 121(10):1885-91. PubMed ID: 24953794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uveitis and Scleritis as a Risk Factor for Mortality.
    Lim JZ; Samalia PD; Sims JL; Niederer RL
    Ocul Immunol Inflamm; 2024 Nov; 32(9):1929-1936. PubMed ID: 38833275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term treatment with rituximab in severe juvenile idiopathic arthritis-associated uveitis.
    Miserocchi E; Modorati G; Berchicci L; Pontikaki I; Meroni P; Gerloni V
    Br J Ophthalmol; 2016 Jun; 100(6):782-6. PubMed ID: 26396026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti CD20 (Rituximab) therapy in refractory pediatric rheumatic diseases.
    Reis J; Aguiar F; Brito I
    Acta Reumatol Port; 2016; 41(1):45-55. PubMed ID: 27115107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence, prevalence, and risk factors of infectious uveitis and scleritis in the United States: A claims-based analysis.
    Zhang Y; Amin S; Lung KI; Seabury S; Rao N; Toy BC
    PLoS One; 2020; 15(8):e0237995. PubMed ID: 32841267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of tocilizumab treatment in refractory ocular inflammatory diseases.
    Silpa-Archa S; Oray M; Preble JM; Foster CS
    Acta Ophthalmol; 2016 Sep; 94(6):e400-6. PubMed ID: 27010181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Follow-Up of Patients with Scleritis After Rituximab Treatment Including B Cell Monitoring.
    van Bilsen K; Vergouwen DPC; van Velthoven MEJ; Missotten TOAR; Rombach SM; van Zelm MC; Berkowska MA; van Hagen PM; Kuijpers RWAM; van Laar JAM
    Ocul Immunol Inflamm; 2024 Sep; 32(7):1268-1273. PubMed ID: 37437135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.